Materials for soft and hard tissue repair

ABSTRACT

Biomaterials and methods and uses for repair or augmentation of tissues are provided. In particular, the invention provides a multi-layered, naturally occurring multi-axial oriented biomaterial comprising predominately type I collagen fibers. The invention further provides methods and uses for repair or augmentation of tissues using biomaterials of the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority Application Ser. No.61/446,956, filed on Feb. 25, 2011, and Application Ser. No. 61/515,803,filed on Aug. 5, 2011, both of which applications are expresslyincorporated herein by reference in their entirety.

FIELD

The invention relates to biomaterials and methods and uses for tissuerepair or augmentation.

INTRODUCTION

Collagen rich, naturally derived tissue has been used to repair herniasand large abdominal wall defects for many years. The use of autologoushuman fascia lata to repair hernia defects was reported by Kirschner in1913. Fascia lata, a dense layer of collagen rich connective tissue, wastaken from a donor site on the lateral (outside) aspect of the thighalong with the accompanying blood vessels, and transplanted to thedefect. This type transplant, with the patient being both the donor andrecipient, is known as an autologous transplant. If there are no bloodvessels brought with the tissue and where circulation is re-establishedby connection of the blood vessels, it is known as a “free graft” ortransplant. If the blood vessels are brought along, and reconnected, itis known as a “vascularized graft” or transplant. A major disadvantageto this type of procedure however, in addition to the large surgicalprocedure required to harvest the tissue, is the risk donor sitemorbidity such as lateral knee instability. Indeed, studies indicatethat this procedure has a high post operative complication rate in therange of 10% to 40%. Recurrent hernia occurred in 10 to 25% of patientsfollowed for up to 29 months using this procedure. One possible reasonfor the failure in this technique is that autologous tissues, especiallyif not vascularized, can be readily resorbed. The inherent limitationsof autologus tissues for soft tissue repair led to the development andwidespread use of synthetic prosthetic mesh materials for hernia andabdominal wall defect repair.

There may as many as 5 million laparotomies performed yearly in theUnited States, and approximately 20% result in incisional hernias.Approximately a quarter of a million ventral incisional hernias arerepaired annually. These figures do not take into account other herniassuch as femoral, inguinal umbilical, parastomal, hiatal, diaphragmaticand Spigelian. Prosthetic mesh repair, instead of suture alone, reducesrecurrence risk by approximately 50%.

Synthetic hernia repair meshes for many years have represented the GoldStandard for surgical repair. The so-called “heavyweight” syntheticmeshes represent the first generation of products. These products arenot without their problems, which include infection, scar formation andpain, adhesion formation with viscera leading to bowel obstruction andfistula. These problems have lead to the development of a variety ofsynthetic and biologic materials for repair of soft tissue defects,weaknesses, hernias or inadequacies. Currently, several synthetic meshesincluding polypropylene (prolene), polyester and polytetrafluoroethylene(PTFE) are used. Some of these polymers have recently been manufacturedin combination with a variety of partially absorbable coatings, designedto limit adhesion formation and the attendant complications. Inaddition, it has become evident that strength alone is not the mostimportant feature in a hernia mesh, but rather the flexibility andcompliance with the body wall are important as well. In an attempt toalleviate some of the problems associated with the “heavyweight”synthetics, so-called “lightweight” synthetic meshes have beenintroduced. These typically have reduced tensile strength compared toheavyweight mesh, but have increased flexibility and greater compliance,with the biomechanical characteristics closer to the abdominal wall.

The drawbacks associated with the synthetic meshes (both heavyweight andlightweight) have lead to the development of “biologic” meshes. Theseproducts are derived from tissues such as acellular human dermal matrix,acellular animal (porcine or bovine) dermal matrix, as well as fromporcine small bowel submucosa. A major advantage of the biologic meshescompared to the synthetics is a reduction in the risk of post-operativeinfection, reduced bowel adhesions and/or fistula formation. However,once in widespread use, the biologics have been shown to have their owndrawbacks: namely laxity and recurrence of hernia over time. Over thepast few years, the problems with these materials have become apparentand re-operation for secondary repair has been required in some cases.To address these issues, it would be advantageous to have a biologichernia repair material with the advantages and properties of the currentbiologic meshes, namely a reduction in infection risk and reduction ofadhesion risk, while simultaneously possessing the biomechanicaladvantages and properties of the current synthetic meshes.

An adjunctive technique to repair hernias large abdominal wall defectsinclude the use of component separation (CST). In CST, the muscle andfascia layers of the patient's abdominal wall are separated bydissection and in some cases transection of the muscle and fasciallayers, and the muscle layers and/or fascial layers are advanced towardthe midline to close large abdominal wall defects. While CST may be usedalone to achieve closure, it also may be used in conjunction withsynthetic or natural prosthetic patch materials to not only increase theability to close large defects, but also to reduce tension on theclosure, leading to decreased risk for recurrence.

SUMMARY

The invention provides a multi-layered, naturally occurring multi-axialoriented biomaterial comprising predominately type I collagen fibers,wherein the biomaterial is suitable for tissue repair or augmentation.The invention further provides methods and uses for repair oraugmentation of a tissue of a recipient mammalian subject (mammalian ornon-mammalian) in need of repair or augmentation utilizing thebiomaterial of the invention. The invention yet further provides methodsand uses for manufacture of a biomaterial suitable for tissue repair oraugmentation.

DESCRIPTION OF THE DRAWINGS

FIGS. 1( a) and (b) illustrate the muscle and fascial layers of thehuman abdominal wall: (a) illustrates the abdominal wall above thearcuate line, where the vertically oriented rectus abdominus is coveredanteriorly and posteriorly by fascia consisting of a combination of allthree distinct muscle layers namely the external oblique, the internaloblique, and the transversus abdominis; and (b) illustrates theabdominal wall below the arcuate line, where the rectus abdominus muscleis covered anteriorly only by fascia, thereby making a very dense,strong connective tissue layer with fibers oriented in multipledirections.

FIG. 2 shows the rectus fascia fiber orientation of a human abdominalwall.

FIGS. 3( a) to (f) are SEM photographs of decellularized and lyophilizedbiomaterial obtained as described herein showing (a) porcine rectussheath fascia surface, (b) porcine rectus sheath fascia cross-sectionalview, (c) bovine shoulder fascia collagen surface view, (d) porcinedermis surface, (e) bovine shoulder fascia layers (100× magnification),(f) bovine shoulder fascia layers (250× magnification), and (g) bovineshoulder fascia collagen with H&E stained sections (40× and 100×magnifactions).

FIG. 4 shows a saggital section of a pre-laparascopic hernia repair viewof an abdominal wall with bowel incarcerated in hernia defect accordingto embodiments of the invention.

FIG. 5 shows a saggital section of a post-laparascopic hernia repairview of a small intestine withdrawn from the abdominal wall defect withsubsequent coverage of the defect utilizing the invention.

FIG. 6 shows a post-laparascopic hernia repair view illustrating thebiomaterial has been surgically secured to the abdominal wall andcovering the hernia defect according to the invention.

FIG. 7 shows thickness measurements of an exemplary bovine fasciabiomaterial according to the invention by a laser micrometry.

FIG. 8 shows suture retention strength measurements of an exemplarybovine fascia biomaterial according to the invention.

FIG. 9 shows tear resistance measurements of an exemplary bovine fasciabiomaterial according to the invention.

FIGS. 10( a) and 10(b) show ball burst testing results of an exemplarybovine fascia biomaterial according to the invention.

FIG. 11( a) shows an image of a pre-repair of a hernia defect accordingto the invention. FIG. 11( b) shows an image of a post-repair of ahernia defect according to the invention.

DETAILED DESCRIPTION

The invention provides biomaterials, and methods and uses ofbiomaterials for tissue repair or augmentation. Invention biomaterialsare suitable for repair or augmentation of soft or hard tissues, such asabdominal wall, muscle, orthopedic applications, etc. The biomaterial isa naturally occurring, multi-layered and multi-axial oriented containingpredominately collagen, e.g., type I collagen. The term “collagen” asused herein refers to all forms of collagen, including those which havebeen processed or otherwise modified. Optionally, the type I collagenfibers may be multi-axial oriented. In certain embodiments, thebiomaterial is multi-laminar. In certain embodiments, the biomaterial ismulti-directional with regard to fiber orientation of the collagenfibers. For example, the fibers have a multi-directional (axial)orientation, and all fibers are not all parallel to each other. Themulti-directional (axial) fiber orientation provides additional strengthto the biomaterial. In various embodiments, the interdigitation of thecollagen fibers are arranged at angles, such as between 1 and 359degrees relative to another fibers, for example, between 45 and 90degrees relative to one another.

In various embodiments, the biomaterial is derived from a mammaliansource or a non-human source, such as a porcine, a bovine, an ovine, anequine, a hircine, or any suitable mammal source. In certainembodiments, the biomaterial includes a multi-density construct derivedfrom one or more of dermis, rectus sheath fascia (e.g., rectus abdominisfascia), shoulder, hind and/or forequarter tissues. In certainembodiments, the biomaterial is derived from dense fibrous, aponeuroticlayers of a mammalian body or non-human body or tissue source, forexample, an oriented fibrous structure of fascia (i.e., porcine rectussheath, bovine forequarter fascia), or fascia lata. In certainembodiments, the biomaterial includes connective tissue, which comprisesa collagen scaffold, optionally free of muscle cells.

The biomaterial is intended to mimic one or more of physiomechanical,biomechanical, and/or anatomical properties of a natural tissue. Themammalian or non-human body or tissue source may mimic the architectureand physicomechanical characteristics of the tissue being repaired, forexample, the abdominal wall of a mammal, human or non-human body. Incertain embodiments, the mammalian or non-human body or tissue sourcemay mimic a connective tissue, or naturally oriented fibers of theabdominal wall (e.g., anterior abdominal wall) of a mammal, human ornon-human body. In certain embodiments, the biomaterial is constructedof multiple layers of tendinous, aponeurotic fibrous collagen fromdiverse mammalian tissue sources forming diverse tissue constructmimicking the naturally oriented fibers of the anterior abdominal wall.As such, the biomaterial may exhibit various properties of an abdominalwall. The biomaterial may mimic the composition and structure of anabdominal wall. The biomaterial may conform to the abdominal wallanatomy.

Anatomy of the Abdominal Wall

The intact rectus sheath consists of multiple layers of strong, dense,fibrous fascial layers of primarily type I collagen which eventuallyencircle the central muscular pillar of the abdomen, the rectusabdominis muscle. Moreover, these musculofascial layers of the anteriorabdominal wall are oriented in three separate and distinct directionswith respect to the midline of the abdomen, an arrangement designed towithstand loading from multiple directions.

The external oblique muscle is the outermost muscular layer. Itoriginates from the lower aspect of the ribs and coursesinferio-medially where it forms a fibrous aponeurosis and attaches atthe linea alba. Both of the external oblique aponeurotic laminae courseanterior to the rectus abdominis muscle above and below the arcuateline. These aponeurotic fibers of the external oblique are oriented at45 degrees with respect to the vertical midline.

The internal oblique musculofascial layer originates from the anterioriliac crest, the inguinal ligament and the posterior aponeurosis of thetransversus abdominis muscle. The musculotendinous fibers of theinternal oblique run superio-medially at a 90 degree angle to theexternal oblique layer, inserting on the cartilages of the lower ribs.At the lateral border of the rectus abdominis muscle and above thearcuate line, the aponeurosis of the internal oblique splits into twolaminae, one course anterior to the rectus abdominis, the other laminaeposterior, encircling the rectus abdominis muscle, contributing to boththe anterior and posterior rectus sheaths (FIG. 1 a). Below the arcuateline, the internal oblique aponeurosis does not split, and both laminaecourse anteriorly along with both laminae of the transversus abdominisforming the anterior rectus sheath (FIG. 1 b). The inferior aponeuroticfibers then pass beneath the spermatic cord, pass through the inguinalcanal and descend posterior to the superficial ring to attach to thepubic crest. The most inferior fibers of the aponeurosis fuse with theaponeurosis of the transversus abdominis to form the conjoint tendon,which courses inferiorly to insert on the pubic crest.

The innermost layer, the transverse abdominis layer, runs horizontallyat a 90 degree angle with respect to the midline, intersecting theexternal and internal oblique layers at a 45 degree angle. This muscleoriginates at the iliac crest and inguinal ligament inferiorly, theinner surface of the lower costal cartilages superiorly and has afibrous origin from the transverse processes of the lumbar vertebrabilaterally. These fibers all run medially to insert at the lateralborder of the rectus muscle. Above the arcuate line, the insertion formsan aponeurosis, contributing to the posterior rectus sheath.

The rectus muscles are vertically oriented, paired muscles forming theprinciple vertical muscle column of the anterior abdominal wall.Inferiorly, the rectus muscle originates from the pubic symphysis andpubic crest. It inserts superiorly on the xiphoid process and the costalcartilages of the lower ribs. The lateral border of each rectus and itssheath merge with the aponeurosis of the external oblique musclelaterally to form the linea semilunaris, a dense collection of tendinousfibers running vertically at the lateral border of the rectus sheath.Toward the midline, the aponeurotic layers coalesce forming anotherdense vertical teninous band of collagen, the linea alba,

Due to the unique and optimal orientation of the collagen fibers withinthese fascial layers and in conjunction with the associated pairedmuscles, the intact abdominal wall provides core strength protection tovital organs, as well as stabilizes and facilitates movement and postureof the trunk.

In the invention, suitable fascia may be harvested either above or belowthe arcuate line of an abdominal wall of a mammalian or non-humansource.

The rectus fascia fiber orientation of a human abdominal wall is shownin FIG. 2. The three layers, namely internal oblique aponeurosis,external oblique aponeurosis and transversus abdominus aponeurosis, areenlarged on the right hand side of the figure showing that the fiberstructures are oriented at right angles to one another. When a herniaoccurs, a defect occurs in one or more of these layers. To repair ahernia defect, a material must be strong enough to withstandintraabdominal pressure and the forces applied to the abdominal walltissue during everyday activity.

The invention employs a fascia, either from the abdominal wall of amammalian or non-human source such as a pig, or a cow (e.g. the shoulderregion of a cow), or a horse. The rectus fascia fiber orientation of theabdominal wall of a mammlian or non-human is similar in architecture asthat of the human. These fascial tissues are decellularized andoptionally freeze-dried prior to implantation to reduce antigenicity,serving as a biological implant with fiber architecture and orientationsimilar to the tissue that is being repaired.

Certain embodiments of the invention provide a biomaterial derived froma mammalian or a non-human fascia. Fascia is composed of strong, thickcollagen fibers aligned along lines of stress similar to the humanabdominal wall. Unlike dermis, it composes of smaller, randomly orientedcollagen fibers. For comparison and illustration purposes, ScanningElectron Microscopy (SEM) was conducted on scaffolds of porcine fascia,bovine fascia and porcine dermis, and the SEM images are shown in FIGS.3( a)-(f).

FIG. 3( a) shows a decellularized and lyophilized porcine rectus sheathfascia surface (70× magnification). The apparent porosity (openstructure) is suitable for cell and tissue ingrowth. FIG. 3( b) shows adecellularized porcine rectus sheath fascia in cross section (70×magnification). The laminar and fibrous structures are shown. There arethree distinct layers where each layer appears to have a separateorientation, which is consistent with the anatomical organization ofrectus sheath fascia. FIG. 3( c) shows a decellularized and lyophilizedbovine shoulder fascia collagen surface (50× magnification). The fibrousstructure with multi-axial fiber orientation is shown. The apparentporosity is suitable for cell and tissue ingrowth. FIG. 3( d) shows adecellularized and lyophilized porcine dermis surface (60×magnification) for comparison. The lack of porosity reduces theopportunity for cell and tissue ingrowth. FIG. 3( e) shows adecellularized and lyophilized bovine shoulder fascia (100×magnification) in cross section. The fascial layers and multi-axialfiber orientation is shown. FIG. 3( f) shows a decellularized andlyophilized bovine shoulder fascia (250× magnification). The discretelayers of collagen with multi-axial fiber orientation is shown. FIG. 3(g) shows a decellularized and lyophilized bovine shoulder collagensurface (light microscope 40× and 100× magnifications). Hyalinized bandsof loose connective tissue are shown. No cell nuclei are identified bylight microscopy within H & E stained sections.

In certain embodiments, the biomaterial may have a plurality of pores,or open spaces between fibers. Typically, the pores or open spaces mayhave a variety of sizes ranging from 20 to 300 microns, or from 50 to200 microns. Certain regions of the biomaterial may have larger pores,ranging in sizes from 100 to 300 microns that may appear as “open spacesbetween fibers.” The pores or open spaces may aid in tissue integrationthus decreasing adhesion formation, especially adhesion formation toviscera. The pores or open spaces may afford tissue ingrowth.

In certain embodiments, the biomaterial may be cross-linked or notcross-linked. The biomaterial may be cross-linked by chemicalmodification to make it more resistant to tearing, degradation, creepand attenuation under functional loading. In certain embodiments, thebiomaterial is perforated or formed into a mesh for improved tissuegrafting or integration.

In certain embodiments, the biomaterial has been processed, modified ortreated to remove cells, fat, protein (e.g., non-collagenous protein),nucleic acid, non-collagenous and/or antigenic components present in themammalian or non-human source from which the biomaterial was derived. Incertain embodiments, the biomaterial has been cleaned, decellularized,de-fatted, purified and/or lyophylized.

While not intending to be bound by theory, it appears that layering thebiomaterial provides the biomaterial with increased or additionalstrength. In certain embodiments, the biomaterial may include at least2, 3, 4, or more layers. In certain embodiments, the biomaterialincludes a plurality of biomaterial elements stitched, sutured, joinedor quilted together to increase size or thickness. Such biomaterialswith increased size or thickness may provide stronger augmentationmaterials or in larger sizes to fit a variety of clinical conditions.

In certain embodiments, the biomaterial may be combined with, treatedwith or formed into a multi-component, or coated, fused or layeredconstruct, with one or more second materials. The second material mayinclude a material that provides the biomaterial with increased oradditional strength. The second material may be autologous (i.e.,harvested from the recipients' own body) or may be xenograft to therecipient (i.e., harvested from a donor, e.g., of the same or differentspecies).

The second material may comprise a synthetic or biologic hard, semi-softor soft, flexible or rigid, mesh, implant, graft, or prosthesis. Thesecond material may limit, prevent, and retard adhesion formation,especially adhesion formation to viscera. The second material mayinclude an absorbable polymer mesh. The second material may include apolymer material or an absorbable layer. Exemplary polymer material thatcan be used in accordance with the invention includes but not limited topolyglycolide, polydioxanone, polypropylene (PP), polyester,polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene(ePTFE), polyetheylene-terephthalat (PET), and mixtures thereof. Varioustypes of absorbable polymer mesh are commercially available includingVicryl® mesh (polylgalactin 910) or Monocryl® (polyglecaprone 25).

The second material may include tissues of a mammalian, human ornon-human recipient. The second material may improve or increaseintegration, grafting, durability or stability of the biomaterial whenintegrated into or combined with tissue of a mammalian, human ornon-human recipient. The second material may include mammalian cellsthat are autologous or are a xenograft with respect to the source of thebiomaterial, or are autologous or are a xenograft with respect to therecipient of the biomaterial. The mammalian cells includes dermis cells,or stem cells, fibroblasts, myoblasts, myocytes, endothelial cells,immune cells (macrophages, monocytes), osteoblasts, or chondroblasts. Incertain embodiments, the biomaterial is a xenograft with respect to apotential recipient of the material. For example, a human recipient mayreceive a non-human biomaterial, for example, from a donor such as a pig(porcine), cow (bovine), sheep (ovine), horse (equine), and goat(hircine).

Second materials also include factors (proteins, hormones, etc.) thatpromote blood vessel growth, tissue integration of the biomaterials. Thesecond material may include an autologous or recombinant growth factor,chemokine or cytokine, such as platelet derived growth factor (PDGF),epidermal growth factor (EGF), insulin like growth factor (IGF)-1,fibroblast growth factor (FGF), transforming grow factor (TGF), such asTGF-beta. The second material may include a bone morphogenic protein(BMP), such as BMP-2, BMP-3, BMP-4, or BMP-7. In certain embodiments,the biomaterial is treated with autologous or recombinant growth factorssuch as PDGF, EGF, IGF-1, FGF, TGF-beta, BMP-2, BMP-3, BMP-4, BMP-7 or acombination thereof.

In certain embodiments, second materials include mitogenic agents suchas autologous platelet rich plasma or allogenic platelet concentrate toenhance cell attachment, migration and wound healing. Accordingly, abiomaterial may be combined with any other second material to providedistinct, additional, or synergistic characteristics, structures orfunctions.

In certain embodiments, a biomaterial has a first rough side and anopposing second dense side. The first rough side may provide for cellingrowth in a recipient. Generally, the second dense side is a morefibrous layer. The second dense side may provide for reduced cellingrowth or adhesion to viscera or bowel of a recipient. The seconddense side may include one, two, or more layers of the same or differentmaterials. For example, the second dense side may include two or moredense layers for more demanding applications such as large hernias orabdominal wall reconstructions. The second dense side may include two ormore of the less dense layers for example as a matrix for stem cellapplication in soft tissue repair. Thus, the biomaterial may have a dualor multi-density construct. In one embodiment, the biomaterial includesbovine, porcine or equine fascia with a more dense layer such as adermis, for example, bovine, porcine or equine dermis.

Various techniques can be used to form the multi-layer construct of thebiomaterial including but not limited to welding, joining, and gluingwith an adhesive. Specifically, the layers may be joined by laserwelding, continuous suturing or stitching, intermittent stitching, orgluing together with cross-linked and not cross-linked collagen basedglue or other biocompatible adhesives. In certain embodiments, thebiomaterial has a quilted, stitched, sutured, or attached multi-layerconstruct, a predominantly flat, folded or rolled sheet. In certainspecific embodiments, the biomaterial is expanded by quilting,stitching, suturing or attaching together two or more biomaterialelements. In specific embodiments, two or more flat sheets may be sewntogether with reinforcing rolled borders. The rolled borders serve toprovide a “memory” function so that the biomaterial may be rolled into acylinder (e.g., scroll), delivered via trocar and then spontaneouslyunrolled itself back into a flat sheet. The rolled borders may beobtained from the linea alba, or constructed from other tendinous of ananimal such as the Achilles tendon, or rectus sheath fascia. In certainembodiments, the biomaterial can be cut or trimmed into a variety ofsizes and shapes such as oval, circular, rectangular or square. Thebiomaterial can be cut without loss of fiber integrity or disruption offiber orientation.

Certain embodiments of the invention provide a biomaterial that exhibitphysical, structural, physical-chemical, bio-mechanical, propertiessuitable for use in accordance with the invention. Such physical,structural, physical-chemical, bio-mechanical, properties can becombined.

For thickness, the biomaterial may have a thickness between 0.2 mm and 5mm, between 0.4 mm and 2.5 mm, or between 0.8 mm and 2.5 mm. In anexemplary embodiment, mean thickness was about 2.7, with a range of 2.1to 3.4 mm. Commercially available hernia repair material ranges from 1.2to 2.8 mm, such that the foregoing biomaterial is suitable for herniarepair and similar applications.

For suture retention strength, the biomaterial may exhibit sutureretention strength of greater than 20 Newtons (N), greater than 50 N,between 4 and 150 N, between 20 and 150 N, or between 20 and 80 N. In anexemplary embodiment, mean suture retention strength was 49 with a rangeof 30 to 66. Commercially available hernia repair material ranges from29-127N, such that the foregoing biomaterial is suitable for herniarepair and similar applications.

For tear resistance, the biomaterial may exhibit tear resistance of atleast 5 N, between 5 and 100 N, between 10 and 90 N, or between 10 and50 N. In an exemplary embodiment, mean tear resistance was 26N with arange of 17 to 38 N. Commercially available hernia repair materialranges from 17-85 N such that the foregoing biomaterial is suitable forhernia repair and similar applications.

For tensile strength (i.e., uniaxial or multiaxial tensile strength),the biomaterial may exhibit tensile strength of at least 20 N, orbetween 50 and 500 N. Alternatively or in addition, a biomaterial mayhave between 2 mega pascals (MPa) and 30 MPa of tensile strength.

For ball burst tensile strength, the biomaterial may exhibit a ballburst tensile strength of at least 50 N/cm, between 50 and 1200 N/cm, orbetween 60 and 1100 N/cm. In an exemplary embodiment, mean ball bursttensile strength was 188 N/cm with a range of 100-286 N/cm. Commerciallyavailable hernia repair available material ranges from 271 to 1028 N/cmsuch that the foregoing biomaterial is suitable for hernia repair andsimilar applications.

For ball burst maximum load, the biomaterial may exhibit ball burstmaximum load of 700 N, with a range of 400 to 1200 N.

For ball burst strain (a measurement of the percentage of stretch at astress of 16N/cm), the biomaterial may exhibit ball burst strain(stretch) of at least 10%, at least 20%, between 5% and 35%, between 10%and 30%, or between 10% and 20%. In an exemplary embodiment, mean ballburst strain (at a stress of 16N/cm) was 15% with a range of 9 to 25%.Commercially available hernia repair ball burst strain ranges from 10 to26% such that the foregoing biomaterial is suitable for hernia repairand similar applications.

Typically, the biomaterial exhibits comparable or better ball bursttensile strength, for exampe, in terms of Maximun Load, and/or TensileStrength at Burst and Strain than other collagen products (see, e.g.,Deeken et al., “Differentiation of biologic scaffold materials throughphysicomechanical, thermal, and enzymatic degradation techniques;”Annals of Surgery, e-publication. Feb. 4, 2012).

In certain embodiments, a method for manufacture of hernia implantcomprises forming at least two independent structures, one biologic andone synthetic and joining structures to form a composite flexiblestructure.

The biomaterial include materials that are stable under conditions usedfor sterilization, for example, with gamma or electron beam radiation,and additionally are stable on storage and in the course of delivery.The biomaterial is usually packaged in a sterile double package prior todelivery to sterilization.

In accordance with the invention, methods and uses of repair oraugmentation of a tissue, such as a soft or a hard tissue, are provided.In certain embodiments, the tissue includes congenitally attenuated,damaged or injured tissue as a result of deformity, disease or trauma.In certain embodiments, the repaired or augmented tissue is abdomen,abdominal wall or muscle.

In one embodiment, a method and use for repair or augmentation of atissue of a recipient mammalian subject in need of repair oraugmentation, includes attaching, joining or affixing thereto abiomaterial described herein to the tissue of the recipient mammliansubject in need of repair or augmentation.

In certain embodiments, a biomaterial for a recipient can be a xenograftor allograft biomaterial. As used herein, the term “xenograft,” refersto tissue transferred from one subject of one species to a recipient ofanother species. As used herein, the term “ allograft,” refers to tissuetransferred from one subject of one species to a recipient of the samespecies (“allogeneic”). With respect to soft tissue for xenografts,porcine, bovine, ovine, equine or hircine can be harvested to formxenografts or allografts according to procedures known to those ofordinary skill in the art.

In one embodiment, a method and use for closure or repair of a wound orcavity in a tissue of a recipient mammlian subject, includes a)providing a biomaterial described herein; b) contacting the wound withthe biomaterial, or positioning, shaping or contouring the biomaterialover the cavity, or introducing the biomaterial into the cavity; c)joining, attaching or affixing the biomaterial to the wound or cavity tosecure said biomaterial; and d) closing said cavity or repairing saidwound in the tissue.

In one embodiment, a method and use of repairing a defect or augmentinga tissue of a recipient mammlian subject in need thereof, includes a)positioning, shaping or contouring the biomaterial described herein tocover a defect or augment the tissue in need thereof; and b) securingthe biomaterial in place.

In one embodiment, a method and use for tissue repair or augmentationincludes delivering to tissue of a recipient mammlian subject abiomaterial described herein, wherein the biomaterial serves to repairor augment the tissue. In a further embodiment, the biomaterial isdelivered through small entrances such as laparoscopic ports, or largeincisions to tissue of a recipient mammlian subject. In a specificembodiment, the biomaterial is delivered to tissue of a recipientmammlian subject according to a laparoscopic surgical procedure.

A saggital view of incarcerated small intestine being trapped within anabdominal wall defect (hernia defect) is illustrated in FIG. 4. Theincarcerated small intestine is withdrawn from the hernia defectaccording to a laparoscopic surgical procedure. A diagramaticrepresentation of a sagittal view of a small intestine withdrawn fromthe abdominal wall defect with subsequent coverage of the defectutilizing the methods and uses of the invention is illustrated in FIG.5. A diagramatic representation of a post-laparascopic hernia repairview illustrating the biomaterial has been surgically secured to theabdominal wall and covering the hernia defect is illustrated in FIG. 6.The figure also shows the location of the laparascopic ports.

Recipient mammalian subjects may be any mammalian species, such as butnot limited to human, dog, cat, horse, pig, and sheep. The recipientmammlian subject may have an abdominal wall defect, trauma, damage, orweakness, a hernia, a fistula, or torn or damaged dura, or an orthopedicdefect trauma, damage, or weakness (e.g., damaged or injured ligament ortendon). In one embodiment, the recipient mammlian subject is sufferingfrom a hernia, such as a ventral incisional hernia; a umbilical,inguinal, femoral, spigelian, parastomal or hiatal hernia; adiaphragmatic hernia; and a lumbar triangle hernia.

In certain embodiments, the recipient mammlian subject is in need ofpelvic floor reconstruction; in need of repair, reinforcement oraugmentation of esophageal perforations or defects; in need of aprotective barrier between vascular anastamosis and bowel; in need of aprotective barrier between viscera following repair; in need ofcorrection or surgery for rectal prolapse; in need of maxillofacial,periodontal or dental surgery: as a soft tissue augmentation material orin the repair of hard and/or soft tissue defects; in need of skeletaldefect repair; in need of orthopedic surgery; in need of urologicsurgery; in need of gynecologic surgery; in need of plastic surgery; orin need of neurosurgery.

In certain embodiments, the recipient mammlian subject is in need of aprotective barrier between vascular anastamosis (i.e., proximal aorticanastamosis) and bowel (i.e., duodenum) as encountered following aorticreconstruction utilizing prosthetic vascular grafts; in need of aprotective barrier between viscera following repair of rectovaginalfistula, rectovesicle fistula; in need of skeletal defect repair in thecraniomaxillofacial or axial skeleton; in need of orthopedic surgery forjoint repair or replacement or in soft tissue repair or augmentation ofjoints or to reinforce, augment, replace weakened, injured, attenuatedor diseased ligamentous, tendinous or joint structures; in need ofurologic surgery for stress urinary incontinence or organ prolapse(e.g., rectal prolapse); in need of gynecologic surgery to correct orreinforce for pelvic floor weakness, as in rectocele, cystocele, vaginalprolapse; in need of plastic surgery to support or reinforce, inhibit orlimit migration of implanted prosthesis, reinforce or augment defects orareas of weakness created by mobilization of soft tissues used invarious reconstructive procedures, or to create, alter or manipulatebody contours; or in need of neurosurgery for dural replacement and/orpatch of a dural defect.

Methods and uses of the invention can be practiced with respect to allvariations of biomaterials set forth herein. For example, in someembodiments, the biomaterial is a xenograft with respect to therecipient mammalian subject. In other embodiments, the biomaterial is anallograft with respect to the recipient mammalian subject. For example,the biomaterial is a decellularized and/or lyophyized xenograft orallograft with respect to the recipient mammalian subject. In certainembodiment, the biomaterial may further include cells or proteins thatare allogeneic or autologous with respect to the recipient mammaliansubject.

Certain embodiments of the invention provides methods for manufacturingbiomaterials suitable for tissue repair or augmentation includes (a)obtaining a multi-layered, naturally occurring multi-axial orientedbiomaterial comprising predominately type I collagen fibers; and (b)processing, modifying or treating the biomaterial to be suitable as axenograft in human and non-human mammal tissue repair or augmentation.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the invention, suitable methods and materials aredescribed herein.

All applications, publications, patents and other references citedherein are incorporated by reference in their entirety. In case ofconflict, the specification, including definitions, will control.

As used herein, the singular forms “a”, “and,” and “the” include pluralreferents unless the context clearly indicates otherwise.

As used herein, numerical values are often presented in a range formatthroughout this document. The use of a range format is merely forconvenience and brevity and should not be construed as an inflexiblelimitation on the scope of the invention. Accordingly, the use of arange expressly includes all possible subranges, all individualnumerical values within that range, and all numerical values ornumerical ranges including integers within such ranges and fractions ofthe values or the integers within ranges unless the context clearlyindicates otherwise. This construction applies regardless of the breadthof the range and in all contexts throughout this document. Thus, forexample, reference to a range of 10-30% includes 10-13%, 11-14%, 12-15%,13-16%, 10-20%, 11-25%, 15-25%, 20-25%, 25-30%, and so forth. Referenceto a range of 10-30% also includes 11%, 12%, 13%, 14%, 15%, 16%, 17%,etc., as well as 11.1%, 11.2%, 11.3%, 11.4%, 11.5%, etc., 12.1%, 12.2%,12.3%, 12.4%, 12.5%, etc., and so forth.

In addition, reference to a range, for example, of 4-150 N (e.g., sutureretention strength) includes 4, 5, 6, 7, 8, 9, 10, . . . 146, 147, 148,149, and 150 as well as 4.1, 4.2, 4.3, 4.4, 4.5, etc., 5.1, 5.2, 5.3,5.4, 5.5, etc., 149.1, 149.2, 149.3, 149.4, 149.5, and any numericalrange within such a ranges, such as 4-10, 4-50, 10-30, 10-60, 10-140,80-130, 80-140, 80-150, etc. In a further example, reference to a rangeof 4-150 N, includes without limitation 10-20, 20-30, 30-40, 40-50,50-60, 60-75, 75-100 N, and any numerical value or range within orencompassing such values.

As also used herein a series of ranges are disclosed throughout thisdocument. The use of a series of ranges includes combinations of theupper and lower ranges to provide another range. This constructionapplies regardless of the breadth of the range and in all contextsthroughout this document. Thus, for example, reference to a series ofranges such as between 5% and 35%, between 10% and 30%, and between 10%and 20%, includes ranges such as 5-30%, 5-35%, 5-20%, 10-35%, 5-10%, andso forth.

The invention is generally disclosed herein using affirmative languageto describe the numerous embodiments. The invention also specificallyincludes embodiments in which particular subject matter is excluded, infull or in part, such as substances or materials, method steps andconditions, protocols, procedures, assays or analysis. Thus, even thoughthe invention is generally not expressed herein in terms of what theinvention does not include, aspects that are not expressly included inthe invention are nevertheless disclosed herein.

A number of embodiments of the invention have been described.Nevertheless, it will be understood that various modifications may bemade without departing from the spirit and scope of the invention.Accordingly, the following examples are intended to illustrate but notlimit the scope of invention described in the claims.

EXAMPLES Example 1

This example describes a biomaterial suitable for tissue repair oraugmentation.

A section of porcine abdominal wall was harvested from a market-size pigin a USDA inspected facility. The animal was certified for humanconsumption and further inspected and certified as such by aveterinarian. The entire abdominal wall was harvested by means of awide, full-thickness circular incision from the costal marginssuperiorly to the pelvic region inferiorly, harvesting as much tissue aspossible and extending posteriorly to the spine. No midline incision wasmade to preserve the integrity of the rectus sheath. The tissue wastransported to an appropriate facility where it was washed thoroughlyusing room temperature water. The skin and superficial fat was removedby mechanical means using sharp and blunt dissection, and the tissue waswashed again with running deionized water. The tissue was disinfected in0.5% sodium hypochlorite solution, and it was frozen for shipping andstorage. Alternatively, to avoid the freezing step, the tissue may beplaced into a solution containing a protease inhibitor and anantibiotic. Examples of appropriate protease inhibitors includesethylenediaminetetracetic acid (EDTA) in concentrations of 1-15 mM or0.2 mM phenymethylsulfonyl flouride (PMSF). Examples of appropriateantibiotics includes solutions such as Penicillin, Gentamycin orVancomycin.

To harvest the fascial layers, the tissue was first allowed to slowlythaw at 20 to 25° C., and additional cleaning and dissection was carriedout until the fascial layer overlying the external oblique wasvisualized. Using blunt and sharp dissection, the fascial layer(multi-laminar and multi-directional) was isolated and cleaned, and asmuch superficial fat was removed as possible. Dissection was carried outlaterally to the medial borders of the oblique muscles and superiorlyand inferiorly to the borders of the tissue. Once the rectus abdominismuscles were identified, a small incision was made bilaterally on thelateral border of the muscle, and the muscle was separated from thefascial layers anteriorly and posteriorly using a combination of bluntand sharp dissection such that the muscle was removed in its entirelyfrom the fascial layers. The fascial tissue was then further treated toremove fat, non-collagenous proteins, blood vessels and cells, leavingbehind a clean, predominately type I collagen multilayered membrane.

To begin the decellularization process, the tissue was rinsed underrunning water, and then immersed in a dilute solution of sodiumhypochlorite for 15 minutes. Chemical de-fatting was carried out bydehydrating the tissue in 100% ethanol for 10 minutes, followed byrotary agitation in a mixture of hexane (70%) and acteone (30%) for 24hours. The tissue was rinsed with 100% ethanol for 10 minutes, and thenwith 70% ethanol for 10 minutes. The rinsed tissue was placed indeinonized water for 1 hour. The water was changed and the tissue wasrinsed for an additional two 1-hour cycles using rotary agitation at 200RPM. Decellularization was accomplished by placing the tissue in asolution of 1% Triton X-100 in phosphate buffer with 1% EDTA for 24hours using rotary agitation at 200 RPM. After the first 2 hours, thesolution was exchanged for fresh solution, soaked for 4 hours andexchanged again after 12 hours. The tissue was then washed again in DIwater for three 1-hour cycles. The tissue was then placed in 1% sodiumdodecyl sulphate (SDS) in phosphate buffer for 24 hours using rotaryagitation at 200 RPM. It was then rinsed in DI water, using three 1-hourcycles and then placed into phosphate buffer for 1 hour. Lyophylizationwas carried out by placing the wet tissue onto stainless steel trays andplacing into a lab scale freeze dryer. Lyophylization was initiated byfreezing with a shelf temperature set to −40° C. and the product washeld for 120 minutes at a pressure 300 millitorr (mtorr). Thetemperature was ramped to −20° C. and the pressure was decreased to 50mtorr over 180 minutes. Next, over the next 400 minutes the temperaturewas ramped to 15° C. at 50 mtorr and then to 20° C. and 50 mtorr overthe next 1200 minutes. Next, the temperature was increased to 30° C. andheld for 30 minutes at which time the cycle was terminated. The freezedryer was then vented with room air and the product was promptly removedfrom the lyophylizer and sealed in polyethelyene bags for storage.

Example 2

This example describes an exemplary biomaterial from bovine shoulderfascia.

A section of bovine shoulder fascia was harvested from a market-sizecalf in a USDA inspected facility. The animal was certified for humanconsumption and further inspected and certified as such by aveterinarian. The shoulder fascia was harvested by careful dissection ofthe thick layer of fascia overlying the deltoid, trapezius andomo-brachialis region after the skin and superficial fat are removed.The tissue was disinfected in mild sodium hypochlorite solution andfrozen for shipping and storage.

To begin processing, the tissue was slowly thawed and additionalcleaning and dissection of fat and loose connective tissue was carriedout until the distinct fascial layers were visualized. Using blunt andsharp dissection, this complex multi-laminar, multi-directional layerwas isolated and cleaned, removing as much superficial fat as possible.

Next, the tissue was rinsed under running, pyrogen-free water, thenimmersed in a dilute solution of 0.5% sodium hypochlorite. The tissuewas then placed into a 1 L jar containing 950 ml of 1% Triton X-100. Thejar was placed on a rotary shaker for 24 hours. The tissue was rinsed DIwater using rotary shaking three times for 30 minutes. The rinsed tissuewas placed into a phosphate buffer solution for 30 minutes, then placedinto a solution of 2% lipase for 8 hours at pH 8.5. The tissue was thenrinsed in deionized water for two 1-hour cycles using rotary agitation,then placed again into the phosphate buffer for 30 minutes. Additionalde-fatting was carried out by placing the tissue in a 1 L jar of 70%ethanol with rotary agitation at 200 RPM for 24 hours followed by a 1hour rinse with deionized water. A second detergent step was then doneusing 0.5% SDS in phosphate buffer at pH 7.5 for 24 hours at 200 RPM.The tissue was again rinsed in DI water using two 1 hour cycles and thenimmersed in phosphate buffer for 30 minutes.

Lyophylization was carried out in a laboratory scale freeze-dryer. Theproduct was placed wet on a stainless steel tray and frozen using aninitial shelf temperature was −40° C. and held at atmospheric pressurefor 120 minutes. The temperature was slowly ramped to 5° C. at apressure of 100 mtorr over a period of 400 minutes, then increased to15° C. and over a period of 400 minutes at 100 mtorr, then increased to20° C. over a period of 400 minutes at 100 mtorr, then increased to 25°C. over 120 minutes at 100 mtorr, then increased to 30° C. over a periodof 40 minutes at 100 mtorr. The lyophylizer was then vented to room airand the cycle was terminated. The product was promptly removed from thechamber in sealed in Tyvek bags for storage.

Example 3

This example describes mechanical testing of an exemplary Bovine FasciaBiomaterial.

The physicomechanical properties of a collagen-based exemplarybiomaterial for hernia repair was evaluated using various means ofmechanical testings described below to determine the suitability forhernia repair application. These tests were performed as described(Deeken et al., “Differentiation of biologic scaffold materials throughphysicomechanical, thermal, and enzymatic degradation techniques;”Annals of Surgery, e-publication. Feb. 4, 2012).

Exemplary scaffolds (biomaterials) were prepared according to theprocess described in Example 2 herein. Thickness of the biomaterial isindicated in FIG. 7.

A. Laser Micrometry

The thickness of six scaffolds (biomaterials) was measured using anLK-081 digital laser micrometer and LK-2101 controller (Keyence,Woodcliff Lake, N.J.). The thickness of each scaffold was measured ninetimes (n=9) and was reported as mean±standard error of the mean (SEM).The results of the laser micrometry test are shown in FIG. 7.

Substantial variability was observed both between different scaffolds ofone embodiment of the biomaterial, i.e., acellular bovine shoulder(ABS), and between different regions within the same embodiment of theABS biomaterial.

B. Biomaterial Suture Retention Strength

Six scaffolds (n=6) measuring 2.5×5.1 cm (1×2 inches) were prepared. Acustom test fixture was utilized in which the scaffold was loaded with agauge length of 2.5 cm (1 inch) and clamped along the upper edge usingpneumatic grips set to 60 psi. A stainless steel wire with a diameter of0.36 mm was passed through the scaffold 1.0 cm from the bottom edge.Polypropylene suture (e.g. size “0” suture) has a diameter of 0.35 mm.Thus, the diameter of the wire was chosen to replicate this type ofsuture as closely as possible. Each scaffold was tested in tension at arate of 300 mm/min (12 in/min) until the suture tore out of thescaffold. The suture retention strength was recorded as the maximum loadsustained by the scaffold in units of Newtons (N) and is reported asmean±SEM. The results of the suture retention strength test are shown inFIG. 8.

All of the scaffolds (biomaterials) individually demonstrated sutureretention strengths exhibit greater than 20N as suggested for herniarepair applications (de Vries Reilingh et al, “Autologous tissue repairof large abdominal wall defects,” Br J Surg. 2007 July; 94(7):791-803,and Deeken et al, (2010) “Physicomechanical evaluation of absorbable andnonabsorbable barrier composite meshes for laparoscopic ventral herniarepair,” Surg Endosc 2010; 25:1451-1552). The overall average of all sixABS scaffolds also demonstrated suture retention strength greater thanthe 20N value suggested for hernia repair applications.

C. Biomaterial Tear Resistance

Tear resistance testing (based on the ASTM specification #D2261-07a) wasperformed. Six scaffolds (n=6) were prepared measuring 2.5×7.6 cm (1×3inches). A 2.5 cm (1 inch) slit was cut from the midline of the 2.5 cmedge of the scaffold toward the center of the scaffold to form two tabsor “pant legs”. The left tab was clamped in the upper grip using apneumatic grip set to 60 psi, and the right tab was clamped in anidentical fashion in the lower grip. Such arrangement yielded a 2.5 cmgauge length (1 inch). The test was conducted in tension at a rate of300 mm/min (12 in/min) until the scaffold tore in half. The “tearstrength” was recorded as the maximum load sustained by the scaffold inunits of Newtons (N) and is reported as mean±SEM. The results of thetear resistance test are shown in FIG. 9.

All of the exemplary scaffolds (except ABS-1) individually demonstratedtear resistance strengths greater than the 20N value suggested forhernia repair applications. The overall average of five ABS scaffolds(ABS-2 excluded from the analysis) also demonstrated tear resistancestrength greater than the 20N value suggested for hernia repairapplications.

D. Ball Burst

Six scaffolds (n=6) measuring 7.5×7.5 cm (3×3 inches) were prepared forburst testing. A custom test fixture was fabricated based on ASTMspecification #D3787-07. Two circular grooved stainless steel plateswere utilized to clamp the scaffold (biomaterial) to prevent slippingduring the test. A 2.5 cm diameter (1 inch) stainless steel ball wasapplied in compression at a rate of 300 mm/min (12 in/min) until itburst through the scaffold. The ultimate tensile stress and the strainat a stress of 16N/cm (i.e., the extent of stretch) were recorded inunits of N/cm and percent respectively and are reported as mean±SEM. Theresults of the ball burst test are shown in FIGS. 10( a) and (b).

All of the scaffolds individually demonstrated ball burst tensilestrengths greater than the 50N/cm value suggested for hernia repairapplications. The overall average of five ABS scaffolds (ABS-3 excludedfrom the analysis) also demonstrated ball burst tensile strength greaterthan the 50N/cm value suggested for hernia repair applications.

All of the scaffolds (except ABS-6) individually demonstrated ball burststrain values in the suggested range of 10-30% for hernia repairapplications. The overall average of five ABS scaffolds (ABS-3 excludedfrom the analysis) also demonstrated ball burst strain value in thesuggested range of 10-30% for hernia repair applications.

Example 4

This example describes exemplary non-limiting applications ofbiomaterials of the invention.

After induction of general anesthesia to a patient, the abdomen isprepped and draped in sterile fashion. Those of skill in the art maycarry out the procedure either laparoscopically or through an openapproach. A variety of techniques and modifications of either approachare also intended.

Laparoscopic Approach

The peritoneal cavity is insufflated with CO₂ and the appropriatetrocars/ports are inserted laterally to gain entrance into theperitoneal cavity. The anterior abdominal wall is examined. Any adherentbowel or omentum is dissected free utilizing sharp dissection or theHarmonic Scalpel, allowing adequate visualization of the hernia defects.FIG. 11( a) shows an image of a pre-repair of hernia defect. Theappropriate size and shape biologic mesh is rolled up and introducedinto the peritoneal cavity through one of the trocars/ports.Subsequently, the mesh is unrolled and appropriately oriented, which isplaced against the anterior abdominal wall in such a fashion that thehernia defect(s) is/are covered and overlapped by about 3-5 cm. The meshis secured to the abdominal with transfascial sutures at “12, 3, 6 and 9o'clock” positions, or by means of a Gra-nee Needle. The mesh is thenfurther secured, between the sutures, at approximately 1 cm intervals,using an endotacking device. FIG. 11( b) shows an image of a post-repairof hernia defect. The CO₂ is evacuated, the trocars/ports are removed,trocar/port sites are sutured, and anesthesia is terminated.

Open Approach

An incision is made over the hernia defect and carried down until theabdominal wall fascia is encountered. The hernia sac is carefullyopened, and any incarcerated contents reduced. Adhesions involving theabdominal wall are divided circumferentially. The appropriate size andshape mesh is then circumferentially secured to the peritoneum andposterior aspect (posterior fascia) of the anterior abdominal wall witha running suture, approximately 3 cm from the edge of the defect.

1. A multi-layered, naturally occurring multi-axial oriented biomaterialcomprising predominately type I collagen fibers, wherein the biomaterialis suitable for tissue repair or augmentation.
 2. The biomaterial ofclaim 1, wherein the biomaterial is derived from a mammalian source. 3.The biomaterial of claim 1, wherein the biomaterial is derived from anon-human source.
 4. The biomaterial of claim 2 or 3, wherein themammalian or non-human source comprises a porcine, a bovine, an ovine,an equine or a hircine.
 5. The biomaterial of any of claims 1 to 3,wherein the biomaterial comprises multiple layers of tendinous,aponeurotic fibrous collagen, optionally wherein the type I collagenfibers are multi-axial oriented.
 6. The biomaterial of any of claims 1to 3, wherein the biomaterial is derived from a dense fibrous,aponeurotic layer of a mammalian or non-human body or tissue source. 7.The biomaterial of claim 6, wherein the mammalian or non-human body ortissue source mimics a connective tissue or abdominal wall of a mammal,human or non-human body.
 8. The biomaterial of claim 6, wherein themammalian tissue source mimics the naturally oriented fibers of theanterior abdominal wall of a mammal, human or non-human body.
 9. Thebiomaterial of any of claims 1 to 3, wherein the biomaterial comprises amulti-density construct derived from one or more of dermis, rectussheath fascia, shoulder, hind and/or forequarter tissues.
 10. Thebiomaterial of any of claims 1 to 3, wherein the biomaterial has beenprocessed, modified or treated to reduce the amount of cells, fat,protein, nucleic acid, non-collagenous and/or antigenic components inthe mammalian or non-human source from which the biomaterial wasderived.
 11. The biomaterial of any of claims 1 to 3, wherein thebiomaterial is substantially free of cells, nucelic acids,non-collagenous proteins, and/or antigenic components in the mammalianor non-human source from which the biomaterial was derived.
 12. Thebiomaterial of any of claims 1 to 3, wherein the biomaterial has beencleaned, decellularized, or de-fatted, or processed to removenon-collagenous proteins, cells, nucelic acids or antigenic componentspresent in the mammalian or non-human source from which the biomaterialwas derived.
 13. The biomaterial of any of claims 1 to 3, wherein thebiomaterial has been purified or lyophilized.
 14. The biomaterial of anyof claims 1 to 3, wherein the biomaterial is suitable for soft or hardtissue repair.
 15. The biomaterial of claim 1, wherein the biomaterialis perforated for improved tissue grafting or integration.
 16. Thebiomaterial of claim 1, wherein the biomaterial is cross-linked or notcross-linked.
 17. The biomaterial of claim 1, wherein the biomaterial iscross-linked by chemical modification.
 18. The biomaterial of claim 16or 17, wherein the cross-linked biomaterial has increased resistance totearing, degradation, creep and attenuation under functional loading.19. The biomaterial of any of claims 1 to 3, wherein the biomaterialcomprises at least 2, 3, 4 or more layers.
 20. The biomaterial of claim1, wherein the biomaterial comprises a soft or hard tissue repair,reinforcing or augmenting graft or implant.
 21. The biomaterial of anyof claims 1 to 3, wherein the biomaterial comprises or is formed into amulti-component, or coated, fused or layered construct, with one or moresecond materials.
 22. The biomaterial of claim 21, wherein the secondmaterial comprises a synthetic or biologic hard, semi-soft or soft,flexible or rigid, mesh, implant, graft, or prosthesis.
 23. Thebiomaterial of claim 22, wherein the mesh comprises an absorbablepolymer mesh.
 24. The biomaterial of claim 21, wherein the secondmaterial comprises a polymer material or an absorbable layer designed tolimit, prevent, reduce or retard adhesion formation.
 25. The biomaterialof claim 21, wherein the polymer material comprises a polyglycolide,polydioxanone, polypropylene (PP), polyester, polytetrafluoroethylene(PTFE), expanded polytetrafluoroethylene (ePTFE), and/orpolyetheylene-terephthalat (PET).
 26. The biomaterial of claim 21,wherein the second material comprises a material that provides thebiomaterial with increased or additional strength.
 27. The biomaterialof claim 21, wherein the second material improves or increasesintegration, grafting, durability or stability of the biomaterial whenintegrated into or combined with tissue of a mammalian, human ornon-human recipient.
 28. The biomaterial of claim 21, wherein the secondmaterial comprises mammalian cells that are autologous or are axenograft with respect to the source of the biomaterial, or areautologous or are a xenograft with respect to the recipient of thebiomaterial.
 29. The biomaterial of claim 28, wherein the cellscomprises dermis cells, or stem cells, fibroblasts, myoblasts, myocytes,edothelial cells, immune cells (macrophages, monocytes), osteoblasts, orchondroblasts.
 30. The biomaterial of claim 21, wherein the secondmaterial comprises a scaffold or lattice.
 31. The biomaterial of claim21, wherein the second material comprises an autologous or recombinantgrowth factor, chemokine or cytokine.
 32. The biomaterial of claim 21,wherein the second material comprises a bone morphogenic protein (BMP).33. The biomaterial of claim 21, wherein the second material comprisesplatelet derived growth factor (PDGF), epidermal growth factor (EGF),insulin like growth factor (IGF)-1, fibroblast growth factor (FGF),transforming grow factor (TGF)-beta, bone morphogenic protein (BMP)-2,BMP-3, BMP-4, or BMP-7.
 34. The biomaterial of claim 1, wherein thebiomaterial is multilaminar.
 35. The biomaterial of claim 1, wherein thebiomaterial is multidirectional with regard to fiber orientation of thecollagen.
 36. The biomaterial in claim 1, wherein the biomaterial has aplurality of pores, wherein the pores aid in tissue grafting orintegration or reducing or decreasing adhesion formation.
 37. Thebiomaterial of claim 1, wherein the biomaterial has a thickness ofbetween 0.2 mm and approximately 5.0 mm.
 38. The biomaterial of claim 1,wherein the biomaterial has a suture retention strength from between4-150 Newtons (N).
 39. The biomaterial of claim 1, wherein thebiomaterial has a suture retention strength of at least 20 N.
 40. Thebiomaterial of claim 1, wherein the biomaterial has a tear resistance ofbetween 5 to 100N.
 41. The biomaterial of claim 1, wherein thebiomaterial has a uniaxial or a multiaxial tensile strength of at least20 N.
 42. The biomaterial of claim 1, wherein the biomaterial has ballburst tensile strength of 25 to 1200 N/cm.
 43. The biomaterial of claim1, wherein the biomaterial has ball burst tensile strength of greaterthan 50 N/cm.
 44. The biomaterial of claim 1, wherein the biomaterialball burst strain (at a stress of 16N/cm) is in the range of 5% to 35%.45. The biomaterial of claim 1, wherein the biomaterial has a firstrough side and an opposing second dense side.
 46. The biomaterial ofclaim 1, wherein the first rough side provides for cell ingrowth in arecipient.
 47. The biomaterial of claim 1, wherein the second dense sideprovides for reduced cell ingrowth or adhesion to viscera or bowel of arecipient.
 48. The biomaterial of claim 1, wherein the tissue comprisesconnective tissue.
 49. The biomaterial of claim 1, wherein thebiomaterial may be cut, configured, formed or shaped without substantialloss of collagen fiber integrity, substantial disruption of collagenfiber orientation or substantial loss of strength.
 50. The biomaterialof claim 1, wherein the biomaterial comprises a quilted, stitched,sutured, or attached multi-layer construct, a predominantly flat, oval,circular, or rectangular, folded or rolled sheet.
 51. The biomaterial ofclaim 50, wherein the multi-layer construct is formed by welding,joining or gluing with an adhesive.
 52. The biomaterial of claim 1,wherein the biomaterial comprises a plurality of biomaterial elementsstitched, sutured, joined or quilted together to increase size orthickness.
 53. The biomaterial of claim 1, wherein the biomaterial iscut, configured, formed or shaped for deployment as a hernia repairimplant, for repair of a body cavity defect, or to strengthen, augmentor reinforce weakened, attenuated tissues, or tissues damaged as aresult of disease, trauma or surgery.
 54. A method for repair oraugmentation of a tissue of a recipient mammalian subject in need ofrepair or augmentation, comprising attaching, joining or affixingthereto the biomaterial of any of claims 1 to 53 to the tissue of therecipient mammlian subject in need of repair or augmentation.
 55. Amethod for closure or repair of a wound or cavity in a tissue of arecipient mammlian subject, comprising: a) providing a biomaterial ofany of claims 1 to 53; b) contacting the wound with the biomaterial, orpositioning, shaping or contouring the biomaterial over the cavity, orintroducing the biomaterial into the cavity; c) joining, attaching oraffixing the biomaterial to the wound or cavity to secure saidbiomaterial; and d) closing said cavity or repairing said wound in thetissue.
 56. A method of repairing a defect or augmenting a tissue of arecipient mammlian subject in need thereof, comprising: (a) positioning,shaping or contouring the biomaterial of any of claims 1 to 53 to covera defect or augment the tissue in need thereof; and (b) securing thebiomaterial in place.
 57. A method for tissue repair or augmentationcomprising delivering to tissue of a recipient mammlian subject abiomaterial of any of claims 1 to 53, wherein the biomaterial serves torepair or augment the tissue.
 58. The method of any of claims 54 to 57,wherein the tissue repaired or augmented comprises a soft or hardtissue.
 59. The method of any of claims 54 to 57, wherein the tissuerepaired or augmented comprises muscle or abdominal wall.
 60. The methodof any of claims 54 to 57, wherein the recipient mammlian subject has anabdominal wall defect, trauma, damage, or weakness, a hernia, a fistula,or torn or damaged dura.
 61. The method of claim 60, wherein the herniacomprises a ventral incisional hernia; a umbilical, inguinal, femoral,spigelian, parastomal or hiatal hernia; a diaphragmatic hernia; or alumbar triangle hernia.
 62. The method of any of claims 54 to 57,wherein the recipient mammlian subject is in need of pelvic floorreconstruction; in need of repair, reinforcement or augmentation ofesophageal perforations or defects; in need of a protective barrierbetween vascular anastamosis and bowel; in need of a protective barrierbetween viscera following repair; in need of correction or surgery forrectal prolapse; in need of maxillofacial, periodontal or dentalsurgery: as a soft tissue augmentation material or in the repair of hardand/or soft tissue defects; in need of skeletal defect repair; in needof orthopedic surgery; in need of urologic surgery; in need ofgynecologic surgery; in need of plastic surgery; or in need ofneurosurgery.
 63. The method of any of claims 54 to 57, wherein therecipient mammlian subject is in need of a protective barrier betweenproximal aortic anastamosis and bowel, as encountered following aorticreconstruction utilizing prosthetic vascular grafts; in need of aprotective barrier between viscera following repair of rectovaginalfistula, rectovesicle fistula; in need of skeletal defect repair in thecraniomaxillofacial or axial skeleton; in need of orthopedic surgery forjoint repair or replacement or in soft tissue repair or augmentation ofjoints or to reinforce, augment, replace weakened, injured, attenuatedor diseased ligamentous or joint structures; in need of urologic surgeryfor stress urinary incontinence or organ prolapse; in need ofgynecologic surgery to correct or reinforce for pelvic floor weakness,as in rectocele, cystocele, vaginal prolapse; in need of plastic surgeryto support or reinforce, inhibit or limit migration of implantedprosthesis, reinforce or augment defects or areas of weakness created bymobilization of soft tissues used in various reconstructive procedures,or to create, alter or manipulate body contours; or in need ofneurosurgery for dural replacement and/or patche of a dural defect. 64.The method of any of claims 54 to 57, wherein the biomaterial is axenograft with respect to the recipient mammalian subject.
 65. Themethod of any of claims 54 to 57, wherein the biomaterial furthercomprises cells or proteins that are autologous with respect to therecipient mammalian subject.
 66. A method for manufacture of abiomaterial suitable for tissue repair or augmentation comprising: (a)obtaining a multi-layered, naturally occurring multi-axial orientedbiomaterial comprising predominately type I collagen fibers; and (b)processing, modifying or treating the biomaterial to be suitable as axenograft in human and non-human mammal tissue repair or augmentation.